Barclays’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-30,316
| Closed | -$459K | – | 5576 |
|
|
2022
Q3 | $459K | Buy |
30,316
+19,080
| +170% | +$222K | ﹤0.01% | 2748 |
|
|
2022
Q2 | $85K | Sell |
11,236
-10,284
| -48% | -$72.5K | ﹤0.01% | 3835 |
|
|
2022
Q1 | $196K | Sell |
21,520
-57,295
| -73% | -$442K | ﹤0.01% | 3438 |
|
|
2021
Q4 | $553K | Buy |
78,815
+35,264
| +81% | +$369K | ﹤0.01% | 3161 |
|
|
2021
Q3 | $498K | Buy |
43,551
+25,814
| +146% | +$377K | ﹤0.01% | 3202 |
|
|
2021
Q2 | $284K | Sell |
17,737
-29,998
| -63% | -$515K | ﹤0.01% | 3389 |
|
|
2021
Q1 | $853K | Sell |
47,735
-34,996
| -42% | -$604K | ﹤0.01% | 2870 |
|
|
2020
Q4 | $1.12M | Sell |
82,731
-47,624
| -37% | -$575K | ﹤0.01% | 2675 |
|
|
2020
Q3 | $1.53M | Sell |
130,355
-47,523
| -27% | -$579K | ﹤0.01% | 2328 |
|
|
2020
Q2 | $2.63M | Buy |
177,878
+146,603
| +469% | +$2.17M | ﹤0.01% | 1860 |
|
|
2020
Q1 | $424K | Sell |
31,275
-12,373
| -28% | -$235K | ﹤0.01% | 3725 |
|
|
2019
Q4 | $1.05M | Buy |
43,648
+13,298
| +44% | +$275K | ﹤0.01% | 3630 |
|
|
2019
Q3 | $584K | Sell |
30,350
-13,569
| -31% | -$311K | ﹤0.01% | 4123 |
|
|
2019
Q2 | $1.3M | Sell |
43,919
-5,549
| -11% | -$214K | ﹤0.01% | 3413 |
|
|
2019
Q1 | $2.35M | Buy |
49,468
+19,262
| +64% | +$848K | ﹤0.01% | 2395 |
|
|
2018
Q4 | $1.09M | Sell |
30,206
-8,469
| -22% | -$397K | ﹤0.01% | 3026 |
|
|
2018
Q3 | $2.38M | Buy |
38,675
+33,760
| +687% | +$2.17M | ﹤0.01% | 2681 |
|
|
2018
Q2 | $332K | Sell |
4,915
-10,139
| -67% | -$567K | ﹤0.01% | 4304 |
|
|
2018
Q1 | $816K | Buy |
15,054
+6,249
| +71% | +$349K | ﹤0.01% | 3461 |
|
|
2017
Q4 | $527K | Buy |
8,805
+3,095
| +54% | +$188K | ﹤0.01% | 3773 |
|
|
2017
Q3 | $277K | Buy |
5,710
+2,279
| +66% | +$124K | ﹤0.01% | 4149 |
|
|
2017
Q2 | $180K | Sell |
3,431
-43,230
| -93% | -$2.01M | ﹤0.01% | 4460 |
|
|
2017
Q1 | $2.12M | Buy |
46,661
+16,315
| +54% | +$728K | ﹤0.01% | 2043 |
|
|
2016
Q4 | $1.15M | Sell |
30,346
-214,819
| -88% | -$8.12M | ﹤0.01% | 2614 |
|
|
2016
Q3 | $9.25M | Buy |
245,165
+239,150
| +3,976% | +$5.27M | 0.01% | 914 |
|
|
2016
Q2 | $106K | Buy |
6,015
+200
| +3% | +$3.24K | ﹤0.01% | 4361 |
|
|
2016
Q1 | $70K | Sell |
5,815
-31,167
| -84% | -$493K | ﹤0.01% | 4594 |
|
|
2015
Q4 | $888K | Sell |
36,982
-145,304
| -80% | -$3.39M | ﹤0.01% | 2716 |
|
|
2015
Q3 | $3.1M | Buy |
182,286
+173,553
| +1,987% | +$3.14M | ﹤0.01% | 1744 |
|
|
2015
Q2 | $149K | Sell |
8,733
-21,421
| -71% | -$393K | ﹤0.01% | 4367 |
|
|
2015
Q1 | $935K | Buy |
30,154
+29,557
| +4,951% | +$857K | ﹤0.01% | 3046 |
|
|
2014
Q4 | $17K | Sell |
597
-4,212
| -88% | -$107K | ﹤0.01% | 6418 |
|
|
2014
Q3 | $96K | Buy |
4,809
+4,625
| +2,514% | +$91.2K | ﹤0.01% | 5366 |
|
|
2014
Q2 | $4K | Sell |
184
-120
| -39% | -$2.08K | ﹤0.01% | 7221 |
|
|
2014
Q1 | $6K | Buy |
304
+182
| +149% | +$3.68K | ﹤0.01% | 7154 |
|
|
2013
Q4 | $2K | Buy |
+122
| New | +$1.59K | ﹤0.01% | 7384 |
|
Barclays's AERI Position: Q4 2022 in Review
Barclays sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 30,316 shares — an estimated $459K sold.
Barclays first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $9.25M in Q3 2016. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Barclays reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Barclays sold 30,316 Aerie Pharmaceuticals shares in Q4 2022, an estimated $459K.
- Barclays first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
- Barclays's Aerie Pharmaceuticals position peaked at $9.25M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.